CSIMarket
 
Amarin Corp Plcuk  (AMRN)
Other Ticker:  
 
 
Price: $0.8593 $-0.01 -1.434%
Day's High: $0.8858 Week Perf: -6.46 %
Day's Low: $ 0.86 30 Day Perf: 2.66 %
Volume (M): 1,025 52 Wk High: $ 1.49
Volume (M$): $ 881 52 Wk Avg: $1.03
Open: $0.87 52 Wk Low: $0.65



 Market Capitalization (Millions $) 351
 Shares Outstanding (Millions) 408
 Employees 1,040
 Revenues (TTM) (Millions $) 280
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) 27
 Capital Exp. (TTM) (Millions $) 1

Amarin Corp Plcuk
Amarin Corporation plc is a biopharmaceutical company that develops and commercializes therapeutic products for the treatment of cardiovascular diseases. The company is based in Dublin, Ireland and its main trading venue is the NASDAQ stock exchange in New York.

Amarin has developed a proprietary technology platform called the VASCEPAe (icosapent ethyl) drug product, which is a prescription medicine that is FDA-approved for the treatment of adult patients with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL). Hypertriglyceridemia is a condition where the levels of triglycerides in the blood are elevated, and this can be a risk factor for the development of cardiovascular diseases like heart attacks and strokes.

VASCEPAe is a highly purified omega-3 fatty acid product that has been shown in clinical trials to reduce triglyceride levels in patients with hypertriglyceridemia. It is also believed that VASCEPAe has other beneficial effects on the cardiovascular system, including reductions in inflammation and improvements in lipid profiles.

Amarin is also conducting research into the use of its omega-3 fatty acid technology for the treatment of other cardiovascular and metabolic diseases. The company has a pipeline of clinical development programs that are focused on a range of indications, including cardiovascular risk reduction in patients with statin therapy, chronic kidney disease, and diabetes mellitus.

Since its inception in 1993, Amarin has raised over $1 billion in funding through a combination of public offerings, private placements, and grants. The company has also entered into partnerships with several pharmaceutical companies, including Kowa Pharmaceuticals America, which is responsible for the commercialization of VASCEPAe in the US.

Despite facing competition from other omega-3 fatty acid products on the market, Amarin has been able to maintain a strong position in the hypertriglyceridemia treatment market due to the unique properties of VASCEPAe. The company's strong financial position and ongoing commitment to research and development make it an attractive investment opportunity for investors who are interested in the biopharmaceutical sector.


   Company Address: Iconic Offices, The Greenway Dublin 2
   Company Phone Number: 6699 020   Stock Exchange / Ticker: NASDAQ AMRN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 Data Further Advance Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action In recent years, there has been a growing interest in understanding the mechanisms behind the potential therapeutic benefits of eicosapentaenoic acid (EPA) a key component found in omega-3 fatty acids. This n...

Published Mon, Apr 8 2024 12:00 PM UTC

Revealing Mechanistic Insights into EPA Sheds Light on VASCEPA/VAZKEPA's Potential Mechanism of ActionAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 Data Further Advance Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action In recent years, there has been a growing interest in understanding the mechanisms behind ...

Product Service News

Unveiling the Potential of VASCEPA/VAZKEPA: New REDUCE-IT Analyses Reveal Promising Benefits in High-Risk Cardiovascular Disease Patients

Published Sat, Apr 6 2024 7:30 PM UTC

The groundbreaking REDUCE-IT trial has demonstrated the remarkable cardioprotective effects of VASCEPA/VAZKEPA (Icosapent Ethyl) in reducing cardiovascular events in high-risk patients. Recently published articles by leading cardiologists shed light on the utility of VASCEPA/VAZKEPA in specific patient subgroups and provide key insights into the impact of baseline High/Low L...

Clinical Study

Evaluating the Benefits of VASCEPA/VAZKEPA and Mechanistic Data on Icosapent Ethyl (IPE)/Eicosapentaenoic Acid (EPA)

Published Mon, Mar 25 2024 12:00 PM UTC

The American College of Cardiology's (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, will showcase new research on the benefits of VASCEPA/VAZKEPA (icosapent ethyl) and reveal mechanistic data on Icosapent ethyl (IPE)/Eicosapentaenoic Acid (EPA). Amarin Corporation plc, a prominent pharmaceutical company, is set to present additional patient subgroup a...

Stock Market Announcement

Amarin Corp Plcuk's Successful Year: Chairman and CEO Highlight Positive Performance

Published Mon, Jan 22 2024 12:30 PM UTC



In a recent press release, Amarin Corporation plc (NASDAQ:AMRN) shared a letter addressed to its shareholders. The letter, authored by Chairman of the Board Odysseas Kostas, M.D. and President & CEO Patrick Holt, provided insights into the company's consistent growth and achievements. This article will summarize the key points from the letter and assess the potent...

Amarin Corp Plcuk

Amarin Corp Plcuk Battles Adverse Industry Conditions, Yet Emerges Triumphantly with Striking Revenue Growth

Amarin Corp Plcuk, a major player in the pharmaceutical preparations industry, faced a challenging third quarter in 2023, as indicated by their increased deficit per share and declining revenue. However, amidst a backdrop of adversity in the industry, Amarin Corp Plcuk managed to shine.
In the third quarter of 2023, Amarin Corp Plcuk saw a deficit per share of $-0.05, which was higher than the previous year's $-0.01 per share and the preceding quarter's $-0.04 per share. This trend is concerning, as it suggests that the company's financial health is deteriorating.






 

Amarin Plcuk's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com